This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Sensyne Health Management

Management criteria checks 0/4

Key information

Alex Snow

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO

Alex Snow (52 yo)

less than a year

Tenure

Mr. Alexander Charles Wallace Snow, also known as Alex, serves as Chief Executive Officer and Director for Sensyne Health plc since April 2022. He was the Chairman of the Board at Exscientia Ltd. Mr. Snow...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Richard Pye	CFO & Executive Director	1.3yrs	UK£261.99k	no data
Lionel Tarassenko	Director of R&D	no data	UK£166.00k	0.013% £ 90.4
Alexander Charles Snow	CEO & Director	less than a year	no data	no data
Alan Payne	Chief Information & Product Officer	2.4yrs	no data	no data
David Ruau	Chief Scientific Officer	less than a year	no data	no data
Julia Wilson	Director of Investor Relations	no data	no data	no data
Laura Hillier	General Counsel & Company Secretary	1.8yrs	no data	no data
Chris Stephenson	Interim HR Director & Chief People Officer	no data	no data	no data
Nick Scott-Ram	Chief of Data Analytics	no data	no data	no data

1.3yrs

Average Tenure

Experienced Management: DSH's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Pye	CFO & Executive Director	1.3yrs	UK£261.99k	no data
Lionel Tarassenko	Director of R&D	3.7yrs	UK£166.00k	0.013% £ 90.4
Alexander Charles Snow	CEO & Director	less than a year	no data	no data
Geoffrey Race	Independent Non-Executive Director	1.3yrs	UK£6.00k	no data
Anthony Bourne	Independent Non-Executive Director	1.4yrs	UK£10.00k	no data
Vishal Gulati	Member of Business Advisory Board	less than a year	UK£35.00k	no data
Michael Norris	Independent Non-Executive Director	1.3yrs	UK£6.00k	0.017% £ 113.1
Bruce Keogh	Independent Non-Executive Chairman	3.8yrs	UK£75.00k	0.0067% £ 45.2
Michael Bewick	Member of Scientific Advisory Board	no data	no data	no data
Mary Hardy	Senior Independent Non-Executive Director	3.8yrs	UK£53.00k	0.013% £ 90.4
David Clifton	Member of Scientific Advisory Board	no data	no data	no data
Peter Watkinson	Member of Scientific Advisory Board	no data	no data	no data

1.3yrs

Average Tenure

58yo

Average Age

Experienced Board: DSH's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

This company listing is no longer active

Sensyne Health Management

Management criteria checks 0/4

Key information

Recent management updates

Sensyne Health plc, Annual General Meeting, Jun 06, 2022

Sensyne Health plc Announces Executive Changes

Insider recently bought €68k worth of stock

High number of new directors

Sensyne Health plc Names Richard Pye as Chief Financial Officer

Sensyne Health plc Announces Appointments

Recent updates

Sensyne Health plc, Annual General Meeting, Jun 06, 2022

Sensyne Health plc Proposes Delisting

Sensyne Health plc Announces Executive Changes

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insider recently bought €68k worth of stock

Sensyne Health plc announced that it expects to receive £11.35 million in funding

Sensyne Health plc announced that it expects to receive £11.35 million in funding

High number of new directors

Full year 2021 earnings released: UK£0.20 loss per share (vs UK£0.17 loss in FY 2020)

Sensyne Health plc Announces Launch of Sensight Data Analytics Platform

Sensyne Grows Medical Research Dataset to 60 Million Patients

Sensyne Health's Magnifeye Ai Software Product Gains Mhra 'Authorisation of Special Use' in Connection with Dhsc Covid-19 Self-Test Lateral Flow Device

Sensyne Health plc Signs A £470,000 Agreement with the Department of Health & Social Care to Conduct the Second Stage of A Pilot Study of Its Magnifeye Technology

Sensyne Health plc Announces SYNE-COV Achieves UK Regulatory Approval

Sensyne Health plc Names Richard Pye as Chief Financial Officer

New 90-day high: €1.84

Sensyne Health plc Licenses Magnifeye Technology to Excalibur

Sensyne Health plc Announces Appointments

Sensyne Health plc Announces the Launch of AI Algorithm for Patient Management

First half 2021 earnings released: UK£0.11 loss per share

Sensyne Health plc Announces Appointment of Tony Bourne as Non-Executive Director, Effective January 31, 2021

New 90-day high: €1.69

Sensyne Health plc Launches MagnifEye Smartphone App

Sensyne Health plc to Report First Half, 2021 Results on Jan 21, 2021

Sensyne Health Appoints Tony Bourne to the Board as Independent Non-Executive Director

Sensyne Health plc Launches First Digital Health Product in the U.S

Sensyne Health plc and Hampshire Hospitals NHS Foundation Trust Sign Strategic Research Agreement

New 90-day high: €1.65

Sensyne Health plc Announces Non-Exclusive Strategic Research Agreement with Somerset NHS Foundation Trust

Sensyne Health Appoints Derek Baird as President, North America

New 90-day high: €1.08

New 90-day high: €1.01

Sensyne Health plc Announces Collaboration with the University of Oxford

Full year earnings released - €0.17 loss per share

Acacia Research Corporation (NasdaqGS:ACTG) acquired 11.8% stake in Sensyne Health plc (AIM : SENS) from Phoenix Wealth LF Woodford Equity Income (FUND:), a fund managed by Link Fund Solutions Limited.

Sensyne Health plc to Report Fiscal Year 2020 Results on Sep 30, 2020

New 90-day high - €0.60

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age